Artal Group’s Verve Therapeutics VERV Stock Holding History

Artal Group’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-300,000	Closed	-$3.98M	–	111
2023 Q3	$3.98M	Hold	300,000	–	–	0.17%	62
2023 Q2	$5.63M	Hold	300,000	–	–	0.17%	63
2023 Q1	$4.33M	Hold	300,000	–	–	0.26%	64
2022 Q4	$5.8M	Sell	300,000 -100,000	-25%	-$2.65M	0.32%	57
2022 Q3	$13.7M	Hold	400,000	–	–	0.59%	37
2022 Q2	$6.11M	Hold	400,000	–	–	0.33%	48
2022 Q1	$9.13M	Hold	400,000	–	–	0.38%	52
2021 Q4	$14.7M	Hold	400,000	–	–	0.4%	55
2021 Q3	$18.8M	Sell	400,000 -100,000	-20%	-$5.88M	0.42%	56
2021 Q2	$30.1M	Buy	+500,000	New	+$20.8M	0.61%	37

Other funds holding VERV

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Artal Group's VERV Position: Q4 2023 in Review

Artal Group sold out of Verve Therapeutics (VERV) in Q4 2023, closing a stake of 300,000 shares — an estimated $3.98M sold.

Artal Group first reported a position in VERV in Q2 2021 and held it in 10 quarters. The position peaked at $30.1M in Q2 2021. 157 funds tracked by Wall St. Rank hold VERV as of Q4 2023.

Artal Group reported no remaining Verve Therapeutics position as of Q4 2023 after selling out during the quarter.
Artal Group sold 300,000 Verve Therapeutics shares in Q4 2023, an estimated $3.98M.
Artal Group first reported a position in Verve Therapeutics in Q2 2021 and held it in 10 quarters.
Artal Group's Verve Therapeutics position peaked at $30.1M in Q2 2021.
157 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2023.

Based on Artal Group's 13F filing for Q4 2023, filed 9 Feb 2024.